Header cover image

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

UpdatedMar 18, 2024
DataAggregated Company Financials
Companies7
  • 7D-9.6%
  • 3M-42.8%
  • 1Y-59.4%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 9.6%, driven by WuXi Biologics (Cayman) declining 17%. Meanwhile, Genscript Biotech actually outperformed within the industry, gaining 20% in the last week. However, the industry is down 59% over the past year. As for the next few years, earnings are expected to grow by 39% per annum.

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 18 Mar 2024HK$120.3bHK$33.3bHK$3.7b47.6x32.7x3.6x
Wed, 14 Feb 2024HK$124.0bHK$32.3bHK$3.0b46.7x41.7x3.8x
Fri, 12 Jan 2024HK$198.5bHK$32.4bHK$3.0b91.8x66.3x6.1x
Sun, 10 Dec 2023HK$208.4bHK$32.3bHK$3.0b81.4x69.7x6.4x
Tue, 07 Nov 2023HK$272.9bHK$30.2bHK$2.7b47.7x101.4x9x
Thu, 05 Oct 2023HK$245.6bHK$30.2bHK$2.7b41.7x91.8x8.1x
Sat, 02 Sep 2023HK$235.0bHK$30.3bHK$2.7b41.8x86.9x7.7x
Mon, 31 Jul 2023HK$236.8bHK$28.5bHK$2.7b23.8x86.2x8.3x
Wed, 28 Jun 2023HK$209.3bHK$28.4bHK$2.7b21.2x77x7.4x
Fri, 26 May 2023HK$235.8bHK$28.9bHK$2.8b21.9x83.6x8.1x
Sun, 23 Apr 2023HK$265.7bHK$29.5bHK$2.9b25.1x90.5x9x
Tue, 21 Mar 2023HK$238.6bHK$26.4bHK$2.1b22.9x115.6x9x
Thu, 16 Feb 2023HK$313.3bHK$26.5bHK$2.1b25.1x149.5x11.8x
Sat, 14 Jan 2023HK$378.5bHK$26.7bHK$2.2b27.6x174.2x14.2x
Mon, 12 Dec 2022HK$288.2bHK$26.0bHK$2.0b27.9x144.4x11.1x
Wed, 09 Nov 2022HK$255.7bHK$25.6bHK$1.9b24.8x137.4x10x
Fri, 07 Oct 2022HK$256.4bHK$25.7bHK$1.9b20.5x134.5x10x
Sun, 04 Sep 2022HK$343.4bHK$26.3bHK$2.1b27.3x167.1x13x
Tue, 02 Aug 2022HK$384.6bHK$22.3bHK$2.1b12x187.6x17.2x
Thu, 30 Jun 2022HK$379.0bHK$22.4bHK$2.1b15.6x182.6x16.9x
Sat, 28 May 2022HK$284.4bHK$22.3bHK$2.1b13.1x138.4x12.7x
Mon, 25 Apr 2022HK$296.8bHK$22.9bHK$2.2b14.3x133.1x12.9x
Wed, 23 Mar 2022HK$314.7bHK$19.2bHK$1.5b21.1x205.9x16.4x
Fri, 18 Feb 2022HK$350.8bHK$18.7bHK$2.8b24.4x124.3x18.7x
Sun, 16 Jan 2022HK$477.6bHK$18.7bHK$2.8b29.6x170.2x25.6x
Tue, 14 Dec 2021HK$528.1bHK$18.7bHK$2.8b37.1x188.6x28.3x
Thu, 11 Nov 2021HK$536.7bHK$18.6bHK$2.8b35.4x192.2x28.9x
Sat, 09 Oct 2021HK$572.2bHK$18.5bHK$2.8b51.7x207.6x31x
Mon, 06 Sep 2021HK$628.0bHK$18.4bHK$2.7b52.9x228.9x34.1x
Wed, 04 Aug 2021HK$679.8bHK$18.4bHK$2.7b56x247.8x37x
Sat, 08 May 2021HK$524.9bHK$15.7bHK$1.4b47.5x363.3x33.5x
Price to Earnings Ratio

320.2x


Total Market Cap: HK$462.5bTotal Earnings: HK$1.4bTotal Revenue: HK$15.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Clinical Research and Equipment Industry Price to Earnings3Y Average 155.5x202220232024
Current Industry PE
  • Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.7x which is lower than its 3-year average PE of 156x.
  • The 3-year average PS ratio of 16.7x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 36% per year over the last three years.
  • Revenues for these companies have grown 29% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?

HK Market1.55%
Healthcare4.12%
Life Sciences-9.62%
Clinical Research and Equipment-9.62%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
1548 Genscript BiotechHK$16.747.9%
+HK$2.6b
-9.0%PS5.4x
1873 Viva Biotech HoldingsHK$0.543.8%
+HK$42.8m
-64.5%PS0.4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

2269

HK$14.76

WuXi Biologics (Cayman)

7D

-16.6%

1Y

-67.3%

1548

HK$16.74

Genscript Biotech

7D

7.9%

1Y

-9.0%

1521

HK$1.53

Frontage Holdings

7D

-3.2%

1Y

-33.2%

6118

HK$1.34

Austar Lifesciences

7D

-7.6%

1Y

-28.0%

2268

HK$16.74

WuXi XDC Cayman

7D

-17.1%

1Y

n/a

8225

HK$0.13

China Health Group

7D

-2.9%

1Y

-50.7%